Annovis Bio

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

Tekla Life Sciences Investors

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its participation in 2021 BIO Digital, the premier biotech event, taking place online June 10-11 & 14-18, 2021.A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to registered attendees beginning at 9:00 a.m....

Annovis Bio to Present at 2021 BIO Digital

With updates from clinical trials expected as soon as this month, anything is possible.

This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

Preliminary data shows ANVS401 protects some types of nerve cells from dying after being infected by gingipains, the virulence factors of P. gingivalisBerwyn, Pennsylvania--(Newsfile Corp. - June 8, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced preliminary data demonstrating ANVS401, the Company's lead drug candidate, protects certain nerve cells from dying after being infected by gingipains, the virulence factors of Porphyromonas gingivalis (P. gingivalis), which have been identified as pathogenic effectors in AD."We initiated...

Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study

There are better options for investors looking to profit from potential Alzheimer's disease treatments.

Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich

Berwyn, Pennsylvania--(Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini will present at the Jefferies Virtual Healthcare Conference 2021 as follows:Date: Friday, June 4, 2021Time: 8:00 a.m. ETWebcast: https://wsw.com/webcast/jeff174/anvs/1866024The presentation will be webcast live and archived for 30 days thereafter.About Annovis Bio Inc.Headquartered in Berwyn, Pennsylvania,...

Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021

Avadel Pharma

Neurocrine Biosciences

SAGE Therapeutics

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Berwyn, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the notable finding that in a test that measures speed, AD and PD patients both respond with a statistically significant increase in correctly coded fields after 25 days of treatment with ANVS401. The test was part of the Company's ongoing Phase 2a study in...

Annovis Bio's ANVS401 Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients

Berwyn, Pennsylvania--(Newsfile Corp. - May 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the engagement of Spencer Stuart, a leading global executive search and leadership advisory firm, to assist the Company in recruiting new candidates to its board and management team. "After a thorough and extensive review of many impressive firms, we...

Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team

Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the closing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of the...

Annovis Bio, Inc. Announces Closing of $50 Million Public Offering

Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ.

Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better

The stock price of Annovis Bio Inc (NYSEAMERICAN: ANVS) decreased by 10% pre-market. This is why it happened.

ANVS Stock: 10% Decrease Pre-Market Explanation

America's Car-Mart

Nordson

Target Hospitality Corp

Some of the stocks that may grab investor focus today are: Wall Street expects Nordson Corporation (NASDAQ: NDSN) to report quarterly earnings at $1.64 per share on revenue of $547.98 million after the closing bell. Nordson shares gained 0.4% to $202.60 in after-hours trading.

5 Stocks To Watch For May 24, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the pricing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of the...

Annovis Bio, Inc. Announces Pricing of Public Offering

On May 21, ANVS doubled on phase 2 data for improved cognition in Alzheimer's disease. The stock has increased more than 600% since my first coverage this January.

Annovis Bio: Positive Phase 2 Alzheimer's Cognition Data Strengthens Bullish Thesis

Agenus

Alpine Immune Sciences

Find out what pushed them up to see if the good times can keep rolling.

3 Biotech Stocks That Jumped Higher Last Week

Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. ThinkEquity, a division of Fordham Financial Management, Inc., is...

Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock

The stock price of Annovis Bio Inc (NYSEAMERICAN: ANVS) increased by over 270% during intraday trading today. This is why it happened.

Annovis Bio (ANVS) Stock: Over 270% Increase Explanation

A dual Alzheimer's-Parkinson's clinical trial is showing highly optimistic results for Annovis, and ANVS stock is up huge because of it. The post ANVS Stock: The Huge News Sending Annovis Bio Rocketing 200% Today appeared first on InvestorPlace.

ANVS Stock: The Huge News Sending Annovis Bio Rocketing 200% Today

Annovis Bio Inc (NYSE:ANVS) shares are trading higher by 180% at $74 Friday morning after the company announced results from its double-blind placebo-controlled study of ANVS401, showing statistically significant cognitive improvement as measured by the ADAS-Cog11. See Also: Annovis Bio's Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement

Why Is Annovis Bio's Stock Surging Higher Today?

Annovis Bio Inc (NYSE: ANVS) has announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401, for Alzheimer's disease (AD), Parkinson's disease (PD). The data comes from 14 AD patients and 14 PD patients.

Annovis Bio's Stock Trading Higher As Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement

Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced new results from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of AD and PD. Patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11...

Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11

Berwyn, Pennsylvania--(Newsfile Corp. - May 20, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini , Ph.D., will participate in the Alzheimer Disease Panel, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday May 26th, 2021, at 11:00 a.m. ET.The panel discussion, led by Dr. Jason McCarthy, Maxim's Senior Managing Director of...

Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - May 19, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from its double-blind, placebo-controlled trial for ANVS401, its lead drug candidate for the treatment of PD and AD. The levels of inflammatory markers in PD patients treated with ANVS401 were significantly lower than before treatment."These positive results confirm ANVS401's potential to...

Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients

News for Annovis Bio Stock (ANVS)